|
Characteristics
|
PORT
|
Non-PORT
|
P-value
|
|---|
|
No. (%)
|
No. (%)
|
|---|
|
Patients (N)
|
70
|
287
| |
|
Age (yr)
| | |
0.55
|
|
≤60
|
43 (61.4)
|
165 (57.5)
| |
|
>60
|
27 (38.6)
|
122 (42.5)
| |
|
Gender
| | |
0.03
|
|
Male
|
35 (50)
|
184 (64.1)
| |
|
Female
|
35 (50)
|
103 (35.9)
| |
|
Smoking history*
| | |
0.004
|
|
Never/light
|
46 (65.7)
|
134 (46.7)
| |
|
Current/heavy
|
24 (34.3)
|
153 (53.3)
| |
|
Clinical N status
| | |
0.45
|
|
cN0,1
|
35 (50)
|
158 (55.1)
| |
|
cN2
|
35 (50)
|
129 (44.9)
| |
|
Pathologic T stage
| | |
0.05
|
|
pT1
|
15 (21.4)
|
65 (22.7)
| |
|
pT2
|
53 (75.7)
|
186 (64.8)
| |
|
pT3
|
2 (2.9)
|
36 (12.5)
| |
|
Type of surgery
| | |
0.01
|
|
Lobectomy
|
67 (95.7)
|
244 (85.0)
| |
|
Sleeve lobectomy
|
3 (4.3)
|
9 (3.1)
| |
|
Pneumonectomy
|
0
|
34 (11.9)
| |
|
Tumor location
| | |
0.13
|
|
RUL
|
26 (37.1)
|
73 (25.4)
| |
|
RML
|
9 (12.9)
|
24 (8.4)
| |
|
RLL
|
12 (17.1)
|
50 (17.4)
| |
|
LUL
|
14 (20.0)
|
90 (31.4)
| |
|
LLL
|
9 (12.9)
|
50 (17.4)
| |
|
Histology
| | |
0.56
|
|
Adenocarcinoma
|
47 (67.2)
|
169 (58.9)
| |
|
Squamous
|
15 (21.4)
|
85 (29.6)
| |
|
Adenosquamous
|
6 (8.6)
|
22 (7.7)
| |
|
Large cell
|
1 (1.4)
|
9 (3.1)
| |
|
Pleomorphic
|
1 (1.4)
|
2 (0.7)
| |
|
N of positive nodes
| | |
0.04
|
|
≤4
|
30 (42.9)
|
162 (56.4)
| |
|
>4
|
40 (57.1)
|
125 (43.6)
| |
|
LNR
| | |
0.002
|
|
≤20%
|
22 (31.4)
|
150 (52.3)
| |
|
>20%
|
48 (68.6)
|
137 (47.7)
| |
|
Involved N2 stations
| | |
0.32
|
|
Single
|
31 (44.3)
|
146 (50.9)
| |
|
Multiple
|
39 (55.7)
|
141 (49.1)
| |
|
Cycles of POCT
| | |
0.08
|
|
<4
|
12 (17.1)
|
78 (27.2)
| |
|
≥4
|
58 (82.9)
|
209 (72.8)
| |
|
Subsequent EGFR-TKI therapy
| |
0.004
|
|
Yes
|
22 (31.4)
|
47 (16.4)
| |
|
No/unknown
|
48 (68.6)
|
240 (83.6)
| |
- Note: *Smoking history was categorized as never/light ex-smokers (<100 cigarettes smoked in the lifetime or smoked ≤10 pack-years, having stopped for ≥15 years) or, the current/heavy ex-smokers.
- Abbreviations: LNR = lymph node ratio (defined as the ratio of metastatic to examined lymph nodes), RUL = right upper lobe, RML = right middle lobe, RLL = right lower lobe, LUL = left upper lobe, LLL = left lower lobe, PORT = postoperative radiotherapy, POCT = postoperative chemotherapy, EGFR-TKI = epidermal growth factor receptor tyrosine kinase inhibitor.
